Dupilumab, a monoclonal antibody that inhibits the action of IL-4 and IL-13 by blocking the shared IL-4 receptor α subunit has been approved by the FDA for moderate–severe atopic dermatitis, asthma, and rhinosinusitis with nasal polyposis treatment. The gene discussed is IL4; the disease is Nasal polyposis.